BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on In Silico experiments

  • Davami, Fatemeh (Biotechnology Research center, Pasteur Institute of Iran Tehran) ;
  • Sardari, Soroush (Biotechnology Research center, Pasteur Institute of Iran Tehran) ;
  • Majidzadeh-A, Keivan (Biotechnology Research center, Pasteur Institute of Iran Tehran) ;
  • Hemayatkar, Mahdi (Biotechnology Research center, Pasteur Institute of Iran Tehran) ;
  • Barkhordari, Farzaneh (Biotechnology Research center, Pasteur Institute of Iran Tehran) ;
  • Enayati, Somayeh (Biotechnology Research center, Pasteur Institute of Iran Tehran) ;
  • Adeli, Ahmad (Biotechnology Research center, Pasteur Institute of Iran Tehran) ;
  • Mahboudi, Fereidoun (Biotechnology Research center, Pasteur Institute of Iran Tehran)
  • Received : 2010.10.21
  • Accepted : 2010.11.20
  • Published : 2011.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Resistance to PAI-1 is a factor which confers clinical benefits in thrombolytic therapy. The only US FDA approved PAI-1 resistant drug is Tenecteplase$^{(R)}$. Deletion variants of t-PA have the advantage of fewer disulfide bonds in addition to higher plasma half lives. A new variant was developed by deletion of the first three domains in t-PA in addition to substitution of KHRR 128-131 amino acids with AAAA in truncated t-PA. The specific activity of this new variant, $570\;IU/{\mu}g$, was found to be similar to those found in full length t-PA (Alteplase$^{(R)}$), $580\;IU/{\mu}g$. A 65% and 85% residual activity after inhibition by rPAI-1 was observed for full length and truncated-mutant form, respectively. This new variant as the first PAI-1 resistant truncated t-PA may offer more advantages in clinical conditions in which high PAI-1 levels makes the thrombolytic system prone to re-occlusion.

Keywords

References

  1. American Heart Association. (2008) Heart Disease and Stroke Statistics, http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008.final.pdf.
  2. Ranby, M., Bergsdorf, N., Pohl, G. and Wallen, P. (1982) Isolation of two variants of native one-chain tissue plasminogen activator. FEBS Lett. 146, 289-292. https://doi.org/10.1016/0014-5793(82)80936-8
  3. Benchenane, K., Lopez-Atalaya, J. P., Fernandez-Monreal, M., Touzani, O. and Vivien, D. (2004) Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27, 155-160. https://doi.org/10.1016/j.tins.2003.12.011
  4. Travis, J. and Salvesen, G. S. (1983) Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52, 655-709. https://doi.org/10.1146/annurev.bi.52.070183.003255
  5. Carrell, R. and Boswell, D. R. (1986) Serpins: the superfamily of plasma serine proteinase inhibitors; in Proteinase Inhibitors, Barrelland, A. and Salvesen, G. (eds.). pp. 403-420, Elsevier, North Holland, Amsterdam, Netherland.
  6. Erickson, L. A., Ginsberg, M. H. and Loskutoff, D. J. (1984) Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J. Clin. Invest. 74, 1465-1472. https://doi.org/10.1172/JCI111559
  7. Hekman, C. M. and Loskutoff, D. J. (1988) Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch. Biochem. Biophys. 262, 199-210. https://doi.org/10.1016/0003-9861(88)90182-8
  8. Higgins, D. L. and Vehar, G. A. (1987) Interaction of onechain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin. Biochemistry 26, 7786-7791. https://doi.org/10.1021/bi00398a038
  9. Wagner, O. F., de Vries, C., Hohmann, C., Veerman, H. and Pannekoek, H. (1989) Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J. Clin. Invest. 84, 647-655. https://doi.org/10.1172/JCI114211
  10. Shohet, R. V., Spitzer, S., Madison, E. L., Bassel-Duby, R., Gething, M. J. and Sambrook, J. F. (1994) Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro. Thromb. Haemost. 71, 124-128.
  11. Paoni, N. F., Keyt, B. A., Refino, C. J., Chow, A. M., Nguyen, H. V., Berleau, L. T., Badillo, J., Pena, L. C., Brady, K. and Wurm, F. M. (1993) A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N ,KHRR 296-299 AAAA). Thromb. Haemost. 70, 307-312.
  12. Li, X. K., Lijnen, H. R., Nelles, L., Van, H. B., Stassen, J. M. and Collen, D. (1992) Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood 79, 417-429.
  13. Nordt, T. K. and Bode, C. (2003) Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 89, 1358-1362. https://doi.org/10.1136/heart.89.11.1358
  14. Baruah, D. B., Dash, R. N., Chaudhari, M. R. and Kadam, S. S. (2006) Plasminogen activators: a comparison. Vascul. Pharmacol. 44, 1-9. https://doi.org/10.1016/j.vph.2005.09.003
  15. Weaver, W. D. (1996) The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Eur. Heart J. 17(Suppl F), 9-15. https://doi.org/10.1093/eurheartj/17.suppl_F.9
  16. Davami, F., Sardari, S., Majidzadeh, A., Hemayatkar, M., Barkhrdari, F., Omidi, M., Azami, M., Adeli, A., Davoudi, N. and Mahboudi, F. (2010) Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments. J. Biomed. Biotechnol. 2010, 108-159.
  17. Burck, P. J., Berg, D. H., Warrick, M. W., Berg, D. T., Walls, J. D., Jaskunas, S. R., Crisel, R. M., Weigel, B., Vlahos, C. J. and McClure, D. B. (1990) Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain. J. Biol. Chem. 265, 5170-5177.
  18. Martin, U., Dorge, L. and Fischer, S. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. Br. J. Pharmacol. 118, 271-276.
  19. http://www.gene.com/gene/products/information/pdf/activase-prescribing.pdf. 2010.
  20. Levine, G. N., Ali, M. N. and Schafer, A. I. (2001) Antithrombotic therapy in patients with acute coronary syndromes. Arch. Intern. Med. 161, 937-948. https://doi.org/10.1001/archinte.161.7.937
  21. Emeis, J. J., van den Hoogen, C. M. and Jense, D. (1985) Hepatic clearance of tissue-type plasminogen activator in rats. Thromb. Haemost. 54, 661-664.
  22. Ouriel, K., Katzen, B., Mewissen, M., Flick, P., Clair, D. G., Benenati, J., McNamara, T. O. and Gibbens, D. (2000) Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J. Vasc. Interv. Radiol. 11, 849-854. https://doi.org/10.1016/S1051-0443(07)61799-0
  23. Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M. J., Sambrook, J. F. and Bassel-Duby, R. S. (1990) Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc. Natl. Acad. Sci. U.S.A. 87, 3530-3533. https://doi.org/10.1073/pnas.87.9.3530
  24. Bagchi, P., Mahesh, M. and Somashekhar, R. (2009) Pharmaco-Informatics: Homology Modelling of the Target Protein (GP1, 2) for Ebola Hemorrhagic Fever and Predicting an Ayurvedic Remediation of the Disease. J. Proteomics. Bioinform. 2, 287-294. https://doi.org/10.4172/jpb.1000088
  25. Pennica, D., Holmes, W. E., Kohr, W. J., Harkins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Yelverton, E., Seeburg, P. H., Heyneker, H. L., Goeddel, D. V. and Collen, D. (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301, 214-221. https://doi.org/10.1038/301214a0
  26. Rouf, S. A., Moo-Young, M. and Chisti, Y. (1996) Tissuetype plasminogen activator: characteristics, applications and production technology. Biotechnol. Adv. 14, 239-266. https://doi.org/10.1016/0734-9750(96)00019-5
  27. Upshall, A., Kumar, A. A., Bailey, M. C., Parker, M. D., Favreau, M. A., Lewison, K. P., Joseph, M. L., Maraganore, J. M. and McKnight, G. L. (1987) Secretion of active human tissue plasminogen activator from the filamentous fungus Aspergillus nidulans. Nature Biotechnology 5, 1301-1304. https://doi.org/10.1038/nbt1287-1301
  28. Soleimani, M., Mahboudi, F., Davoudi, N., Amanzadeh, A., Azizi, M., Adeli, A., Rastegar, H., Barkhordari, F. and Mohajer-Maghari, B. (2007) Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae. Biotechnol. Appl. Biochem. 48, 55-61. https://doi.org/10.1042/BA20060217
  29. Opdenakker, G. M. M. and It, P. (1996) Protease inhibitors, a DNA construct for the expression of a protease and a process for measuring proteases and/or protease inhibitors. (EP0736302).
  30. Hamsten, A., de, F. U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C., Blomback, M. and Wiman, B. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2, 3-9.
  31. Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M. J. and Sambrook, J. F. (1989) Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 339, 721-724. https://doi.org/10.1038/339721a0
  32. Deleage, G. and Roux, B. (1987) An algorithm for protein secondary structure prediction based on class prediction. Protein Eng. 1, 289-294. https://doi.org/10.1093/protein/1.4.289
  33. Heussen, C. and Dowdle, E. B. (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 102, 196-202. https://doi.org/10.1016/0003-2697(80)90338-3
  34. Pandya, B. V., Gabriel, J. L., O'Brien, J. and Budzynski, A. Z. (1991) Polymerization site in the beta chain of fibrin: mapping of the B beta 1-55 sequence. Biochemistry 30, 162-168. https://doi.org/10.1021/bi00215a024
  35. Chmielewska, J., Ranby, M. and Wiman, B. (1983) Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb. Res. 31, 427-436. https://doi.org/10.1016/0049-3848(83)90407-3
  36. Krishnamurti, C., Keyt, B., Maglasang, P. and Alving, B. M. (1996) PAI-1-resistant t-PA: low doses prevent fibrin deposition in rabbits with increased PAI-1 activity. Blood 87, 14-19.
  37. Green George, D. J. (1989) Purified type I and type II t-PA. (WO 89/09820).
  38. Kohnert, U., Rudolph, R., Verheijen, J. H., Weening-Verhoeff, E. J., Stern, A., Opitz, U., Martin, U., Lill, H., Prinz, H., Lechner, M. and Lechner, M. (1992) Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng. 5, 93-100. https://doi.org/10.1093/protein/5.1.93

Cited by

  1. Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats vol.7, 2017, https://doi.org/10.1038/srep43028
  2. Tissue Plasminogen Activator: A Literature Review vol.3, pp.1, 2016, https://doi.org/10.5812/archneurosci.30452
  3. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties vol.67, 2014, https://doi.org/10.1016/j.enzmictec.2014.09.005
  4. A fed-batch based cultivation mode inEscherichia coliresults in improved specific activity of a novel chimeric-truncated form of tissue plasminogen activator vol.114, pp.2, 2013, https://doi.org/10.1111/jam.12059
  5. Expression of a Novel Chimeric-Truncated tPA in Pichia pastoris with Improved Biochemical Properties vol.56, pp.12, 2014, https://doi.org/10.1007/s12033-014-9794-5